Clinical Trials

25 enrolled

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06034002 2026-03-16

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

230 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06150157 2026-03-16

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

220 enrolled

Tumor-Agnostic

Neoplasms

NCT06120140 2026-03-13

COCOON

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Phase 2 Completed

171 enrolled

Phase 1 Not yet recruiting

Burkitt Lymphoma, Leukemia

NCT07464951 2026-03-11

CART123

30 enrolled

Phase NA Not yet recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Recruiting

54 enrolled

Lymphoid

Hodgkin Disease

NCT07454226 2026-03-06

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

30 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

83 enrolled

Lymphoid

Lymphoma, Recurrence

NCT04279847 2026-02-25

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT07025538 2026-02-23

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 1 Suspended

42 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT03514069 2026-02-19

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

60 enrolled

CNS

Glioblastoma, Glioma

NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

50 enrolled

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT07359859 2026-02-17

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

40 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT05592015 2026-02-10

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

30 enrolled

Leukemia, Large Granular Lymphocytic

NCT05936359 2026-02-10

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

225 enrolled

Phase 2 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

34 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03610971 2026-01-29

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07366801 2026-01-26

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Phase 2/3 Recruiting

64 enrolled

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07356245 2026-01-21

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

DermatologicLymphoidOther hematologic neoplasm

44 enrolled

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06768476 2026-01-16

AML

12 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT07219576 2026-01-13

PRISM

Phase 1/2 Recruiting

40 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT03571321 2026-01-09

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

60 enrolled

Polycythemia Vera, Thrombocythemia, Essential

NCT07128381 2026-01-05

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Phase 1/2 Recruiting

66 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

36 enrolled

Leukemia, Prolymphocytic, T-Cell

NCT06991101 2025-12-26

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

190 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Classical hematologyOther hematologic neoplasm

124 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT07297914 2025-12-22

FORUM2

Phase 2/3 Not yet recruiting

1,000 enrolled

Graft vs Host Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05088356 2025-12-19

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

60 enrolled